Fatemeh Zanjanchi Neko, Isa Mohammadi Zeidi, Hadi Morshedi, Banafsheh Mohammadi Zeidi, Mohammad Reza Maleki, Amir Pakpoor Hajia
Objective: The aim of the study was to determine the effect of the educational intervention based on the health action process approach (HAPA) model on the level of knowledge, metabolic indicators, psychological constructs and physical activity status in type 2 diabetes (T2D) patients in 2022–2023. Material and methods: The present study was a randomized controlled trial and 100 T2D patients were equally assigned to experimental and control groups using multistage random sampling. The educational program included six online sessions, targeted pamphlets, educational audio files and reminder messages. Data were collected before and 3 months after intervention with demographic items, awareness scale, constructs of HAPA model, IPAQ-s, HbA1c and fasting blood glucose (FBG). Data were entered to SPSS 25.0 and analyzed with chi-square, ANOVA and ANCOVA. Results: After controlling the effect of the pre-test variable, the mean of the HAPA model constructs and mean of physical activity improved significantly in posttest. In addition, educational intervention explained 30.2%, 57.8%, 33.2%, 64.4%, 76.3%, 25.3%, 24.6%, 36.1% and 36.9% of the variance of health awareness, risk perception, outcome expectancy, action self-efficacy, maintenance self-efficacy, action plan, coping plan, behavioral intention and physical activity, respectively. In addition, the mean of FBG and HbA1c in the experimental group improved significantly after the intervention by controlling the pre-test effect (p < 0.001). Conclusions: Providing theory-based educational interventions through the web and mobile can increasingly promote the effectiveness of cognitive behavioral interventions and facilitate the process of behavior change in T2D.
{"title":"Effectiveness of Theory-Based Intervention on Knowledge Level, Psychological Constructs, Metabolic Index and Physical Activity Status in Patients with Type 2 Diabetes: Application of the Health Action Process Approach (HAPA) Model","authors":"Fatemeh Zanjanchi Neko, Isa Mohammadi Zeidi, Hadi Morshedi, Banafsheh Mohammadi Zeidi, Mohammad Reza Maleki, Amir Pakpoor Hajia","doi":"10.5603/cd.96203","DOIUrl":"https://doi.org/10.5603/cd.96203","url":null,"abstract":"Objective: The aim of the study was to determine the effect of the educational intervention based on the health action process approach (HAPA) model on the level of knowledge, metabolic indicators, psychological constructs and physical activity status in type 2 diabetes (T2D) patients in 2022–2023. Material and methods: The present study was a randomized controlled trial and 100 T2D patients were equally assigned to experimental and control groups using multistage random sampling. The educational program included six online sessions, targeted pamphlets, educational audio files and reminder messages. Data were collected before and 3 months after intervention with demographic items, awareness scale, constructs of HAPA model, IPAQ-s, HbA1c and fasting blood glucose (FBG). Data were entered to SPSS 25.0 and analyzed with chi-square, ANOVA and ANCOVA. Results: After controlling the effect of the pre-test variable, the mean of the HAPA model constructs and mean of physical activity improved significantly in posttest. In addition, educational intervention explained 30.2%, 57.8%, 33.2%, 64.4%, 76.3%, 25.3%, 24.6%, 36.1% and 36.9% of the variance of health awareness, risk perception, outcome expectancy, action self-efficacy, maintenance self-efficacy, action plan, coping plan, behavioral intention and physical activity, respectively. In addition, the mean of FBG and HbA1c in the experimental group improved significantly after the intervention by controlling the pre-test effect (p < 0.001). Conclusions: Providing theory-based educational interventions through the web and mobile can increasingly promote the effectiveness of cognitive behavioral interventions and facilitate the process of behavior change in T2D.","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135461726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mridul Bera, Amit Gupta, Rishad Ahmed, Arjun Baidya, Mrinal Kanti Guha
Objective: The aim of the study was to determine and evaluate the prevalence of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes and the impact of diabetes on lung function and the severity of the COPD. Materials and methods: This was a retrospective observational study conducted in a private clinic setup among 1200 patients and was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology Statement (STROBE). Chronic Obstructive Lung Disease (GOLD) criteria, 2023 were used to diagnose COPD and for diabetes mellitus (DM) were executed according to the American Diabetes Association (ADA) and International Diabetes Federation (IDF) consensus statement. Results: The prevalence of type 2 diabetes (T2D) was 27% among 1200 COPD patients. Among 335 patients with diabetes 37% had newly detected T2D. Prevalence in mild, moderate, severe, and very severe COPD among patients having documented T2D was 14.6%, 18.8%, 37%, and 29.5%, respectively. Furthermore, among diabetes patients 7.5% were having HbA1c < 7%, 63.9% were having HbA1c 7–10% and 28.6% were having HbA1c > 10%. As compared to people without diabetes (56.64 ± 3.55), in patients with diabetes (46.22 ± 4.19) there was a severe decline in lung function (mean FEV1) and it was statistically significant (p = 0.001). Comorbidities, as shown by multivariate Cox proportional hazards analysis, including hypertension (HR, 1.902; 95% CI, 1.261–2.403), dyslipidemia (HR, 1.391; 95% CI, 1.172–1.198), cerebrovascular disease (HR, 1.532; 95% CI, 1.132–2.008), coronary artery disease (HR, 1.427; 95% CI, 1.079–1.830), kidney disease (HR, 1.006, 95% CI, 0.833–1.397) and liver disease (HR, 1.083, 95% CI, 0.821–1.427) were independent clinical factors associated with T2D. Conclusions: Chronic obstructive pulmonary disease is one of the comorbidities found in patients with T2D. A significant number of cases of new-onset diabetes are observed among patients with pre-existing COPD. Therefore, the outcome of this research advocates that targeted surveillance and management of diabetes are important in clinical care of the COPD population.
{"title":"Prevalence and Severity of Chronic Obstructive Pulmonary Disease in People with Type 2 Diabetes: A Cross-Sectional Study","authors":"Mridul Bera, Amit Gupta, Rishad Ahmed, Arjun Baidya, Mrinal Kanti Guha","doi":"10.5603/cd.95828","DOIUrl":"https://doi.org/10.5603/cd.95828","url":null,"abstract":"Objective: The aim of the study was to determine and evaluate the prevalence of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes and the impact of diabetes on lung function and the severity of the COPD. Materials and methods: This was a retrospective observational study conducted in a private clinic setup among 1200 patients and was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology Statement (STROBE). Chronic Obstructive Lung Disease (GOLD) criteria, 2023 were used to diagnose COPD and for diabetes mellitus (DM) were executed according to the American Diabetes Association (ADA) and International Diabetes Federation (IDF) consensus statement. Results: The prevalence of type 2 diabetes (T2D) was 27% among 1200 COPD patients. Among 335 patients with diabetes 37% had newly detected T2D. Prevalence in mild, moderate, severe, and very severe COPD among patients having documented T2D was 14.6%, 18.8%, 37%, and 29.5%, respectively. Furthermore, among diabetes patients 7.5% were having HbA1c < 7%, 63.9% were having HbA1c 7–10% and 28.6% were having HbA1c > 10%. As compared to people without diabetes (56.64 ± 3.55), in patients with diabetes (46.22 ± 4.19) there was a severe decline in lung function (mean FEV1) and it was statistically significant (p = 0.001). Comorbidities, as shown by multivariate Cox proportional hazards analysis, including hypertension (HR, 1.902; 95% CI, 1.261–2.403), dyslipidemia (HR, 1.391; 95% CI, 1.172–1.198), cerebrovascular disease (HR, 1.532; 95% CI, 1.132–2.008), coronary artery disease (HR, 1.427; 95% CI, 1.079–1.830), kidney disease (HR, 1.006, 95% CI, 0.833–1.397) and liver disease (HR, 1.083, 95% CI, 0.821–1.427) were independent clinical factors associated with T2D. Conclusions: Chronic obstructive pulmonary disease is one of the comorbidities found in patients with T2D. A significant number of cases of new-onset diabetes are observed among patients with pre-existing COPD. Therefore, the outcome of this research advocates that targeted surveillance and management of diabetes are important in clinical care of the COPD population.","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135461388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)
《临床糖尿病学》是一本双月刊，开放获取的科学和教育期刊，它是通过结合实验和临床糖尿病学的科学假设而创建的(Diabetologia Doświadczalna i Kliniczna)。
{"title":"The Effect of the COVID-19 Crisis on Metabolic Control of Patients with Type 2 Diabetes in Tunisia: A Cross-Section and Retrospective Cohort Study","authors":"Melika Chihaoui, Chayma Bel Hadj Sliman, Anis Grassa, Nadia Khessairi, Fatma Chaker, Meriem Yazidi, Bessam Hammami, Moncef Feki, Ibtissem Oueslati","doi":"10.5603/cd.97313","DOIUrl":"https://doi.org/10.5603/cd.97313","url":null,"abstract":"Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135461527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)
《临床糖尿病学》是一本双月刊，开放获取的科学和教育期刊，它是通过结合实验和临床糖尿病学的科学假设而创建的(Diabetologia Doświadczalna i Kliniczna)。
{"title":"Association between Random Glucose Level, HbA1c and COVID-19 Mortality: A Single Center, Cross-Sectional Study","authors":"Faizal Awaluddin, Husaini Umar, Sudirman Katu, Syakib Bakri, Andi Makbul Aman, Harun Iskandar, Arifin Seweng","doi":"10.5603/cd.96589","DOIUrl":"https://doi.org/10.5603/cd.96589","url":null,"abstract":"Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135461537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)
《临床糖尿病学》是一本双月刊，开放获取的科学和教育期刊，它是通过结合实验和临床糖尿病学的科学假设而创建的(Diabetologia Doświadczalna i Kliniczna)。
{"title":"Beyond Diabetes Management: Unraveling Metformin’s Long-Term Effects on Vitamin B12","authors":"Gurusha Bahl, Md Sadique Hussain, Nikita Saraswat, Mohit Agrawal","doi":"10.5603/cd.97473","DOIUrl":"https://doi.org/10.5603/cd.97473","url":null,"abstract":"Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135461548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Karina, Grady Krisandi, I. Rosadi, T. P. Sibuea, J. A. Biben, Krista Ekaputri, Azza Maryam, Sulaeha Ad, S. Sobariah, I. Afini, Tias Widyastuti, A. Zakiyah, D. Ernanda, N. Aini
Objective: A cutting edge potential treatment of type 2 diabetes (T2D) is the use of cellular therapy. One recent method is the use of combination of stromal vascular fraction (SVF) and autologous activated platelet-rich plasma (aaPRP). This study is aimed to evaluate the efficacy of SVF combined with aaPRP to treat T2D. Materials and methods: Patients with T2D who un - derwent SVF and aaPRP treatment were recruited in this study. The lipoaspirate was digested by H-Remedy enzyme and centrifuged to isolate SVF. Blood was drawn from the patients and the aaPRP was isolated. The combination of autologous SVF and aaPRP was administered intravenously to each patient. Patients’ 1-month and 3-month post-therapy HbA1c level were statistically analyzed to their baseline level. Results: A total of 39 patients, 28 male and 11 female, with T2D with mean age of 59±11 years and baseline HbA1c of 8.31 g/dL were included in this study. Com - bination of SVF and aaPRP treatment in T2D resulted in a statistically significant decrease in HbA1c level to 7.58 g/dL at 1 month and to 7.63 g/dL at 3 months post-therapy, while a decrease in HbA1c was still observed at 6 and 12 months after therapy. Conclusions: SVF combined with aaPRP may have potential to reduce HbA1c levels in patients with T2D. Further research is needed to confirm the findings of our research. (Clin Diabetol 2023; 12; 4: 247–252) Clinical trial registration number: NCT05925829
{"title":"Stromal Vascular Fraction and Autologous Activated Platelet-Rich Plasma Combination in Treatment of Type 2 Diabetes: A Single Center Retrospective Study","authors":"K. Karina, Grady Krisandi, I. Rosadi, T. P. Sibuea, J. A. Biben, Krista Ekaputri, Azza Maryam, Sulaeha Ad, S. Sobariah, I. Afini, Tias Widyastuti, A. Zakiyah, D. Ernanda, N. Aini","doi":"10.5603/dk.a2023.0027","DOIUrl":"https://doi.org/10.5603/dk.a2023.0027","url":null,"abstract":"Objective: A cutting edge potential treatment of type 2 diabetes (T2D) is the use of cellular therapy. One recent method is the use of combination of stromal vascular fraction (SVF) and autologous activated platelet-rich plasma (aaPRP). This study is aimed to evaluate the efficacy of SVF combined with aaPRP to treat T2D. Materials and methods: Patients with T2D who un - derwent SVF and aaPRP treatment were recruited in this study. The lipoaspirate was digested by H-Remedy enzyme and centrifuged to isolate SVF. Blood was drawn from the patients and the aaPRP was isolated. The combination of autologous SVF and aaPRP was administered intravenously to each patient. Patients’ 1-month and 3-month post-therapy HbA1c level were statistically analyzed to their baseline level. Results: A total of 39 patients, 28 male and 11 female, with T2D with mean age of 59±11 years and baseline HbA1c of 8.31 g/dL were included in this study. Com - bination of SVF and aaPRP treatment in T2D resulted in a statistically significant decrease in HbA1c level to 7.58 g/dL at 1 month and to 7.63 g/dL at 3 months post-therapy, while a decrease in HbA1c was still observed at 6 and 12 months after therapy. Conclusions: SVF combined with aaPRP may have potential to reduce HbA1c levels in patients with T2D. Further research is needed to confirm the findings of our research. (Clin Diabetol 2023; 12; 4: 247–252) Clinical trial registration number: NCT05925829","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83846017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Srinidhi Rai, S. Sreelatha, Nayana Devang, Priyadharshini Alva, A. V. Raveendran
Objective: Diabetes mellitus (DM) is associated with complications affecting the quality of life. Interest-ingly, the gut microbiota is closely related to glucose metabolism. This narrative review introduces the characteristics of the gut microbiota in DM, describes the modulation of host glycemic control by the gut microbiota, characteristics of intestinal permeability, mechanisms of diabetic cognitive impairment (DCI), and the role of brain–gut–microbiota axis in DM. Materials and methods: The literature search was performed in Medline, Scopus, WOS, and PubMed databases using the keywords gut microbiota, DM, intestinal permeability, and DCI. Results: Dysbiosis of gut microbiota causes intestinal barrier disruption resulting in the entry of intestinal bacteria and their metabolites into the circulatory system, which may disturb insulin sensitivity, glucose metabolism, and immune homeostasis. Gut microbiota plays a critical role in regulating systemic insulin sensitivity and energy metabolism. Intestinal barrier dysfunction induced by hyperglycemia is considered to be the underlying mechanism of systemic infection and inflammatory response in patients with diabetes. Both dysbacteriosis and cytokines will lead to the intestinal barrier and blood–brain barrier dysfunction, facilitating harmful substances (advanced glycated end products) to access neurons, and thus contribute to the development of DCI. The modulation of intestinal permeability through nutritional interventions may represent a potential prevention target for DM. Conclusions: The clinical evidence for the association between hyperglycemia and intestinal barrier dysfunction in humans is scarce. Further clinical studies are needed to provide more insight by studying the intestinal barrier integrity markers and glycemic status and their association with cognitive status. (Clin Diabetol 2023; 12; 4: 261–271)
{"title":"The Microbiota–Gut–Brain Axis and Diabetic Cognitive Impairment: A Memorable Journey","authors":"Srinidhi Rai, S. Sreelatha, Nayana Devang, Priyadharshini Alva, A. V. Raveendran","doi":"10.5603/dk.a2023.0025","DOIUrl":"https://doi.org/10.5603/dk.a2023.0025","url":null,"abstract":"Objective: Diabetes mellitus (DM) is associated with complications affecting the quality of life. Interest-ingly, the gut microbiota is closely related to glucose metabolism. This narrative review introduces the characteristics of the gut microbiota in DM, describes the modulation of host glycemic control by the gut microbiota, characteristics of intestinal permeability, mechanisms of diabetic cognitive impairment (DCI), and the role of brain–gut–microbiota axis in DM. Materials and methods: The literature search was performed in Medline, Scopus, WOS, and PubMed databases using the keywords gut microbiota, DM, intestinal permeability, and DCI. Results: Dysbiosis of gut microbiota causes intestinal barrier disruption resulting in the entry of intestinal bacteria and their metabolites into the circulatory system, which may disturb insulin sensitivity, glucose metabolism, and immune homeostasis. Gut microbiota plays a critical role in regulating systemic insulin sensitivity and energy metabolism. Intestinal barrier dysfunction induced by hyperglycemia is considered to be the underlying mechanism of systemic infection and inflammatory response in patients with diabetes. Both dysbacteriosis and cytokines will lead to the intestinal barrier and blood–brain barrier dysfunction, facilitating harmful substances (advanced glycated end products) to access neurons, and thus contribute to the development of DCI. The modulation of intestinal permeability through nutritional interventions may represent a potential prevention target for DM. Conclusions: The clinical evidence for the association between hyperglycemia and intestinal barrier dysfunction in humans is scarce. Further clinical studies are needed to provide more insight by studying the intestinal barrier integrity markers and glycemic status and their association with cognitive status. (Clin Diabetol 2023; 12; 4: 261–271)","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87471757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study was aimed to determine the ge-netic background of pediatric patients with a clinical diagnosis of maturity-onset diabetes of youth (MODY). Materials and methods: In this study, MODY-related genes of 80 pediatric patients diagnosed with MODY in Türkiye between January 2016 and January 2022 were investigated using three different large gene panels and next-generation sequencing. Results: Causal variants were detected in the genes investigated in 16 (20%) of 80 patients included in the study. The GCK gene was responsible for the clinical findings in 13 (82%) of 16 patients with a molecular diagnosis, and the HNF1A , HNF1B , and ABCC8 genes in the remaining three patients. This study identified six of the detected genomic variants for the first time in the literature. Conclusions: MODY is a group of diseases that differ from each other in terms of clinical findings, treatment, progression, genetic etiopathogenesis and incidence. For this reason, genetic analyses using multigene panels will enable accurate identification of MODY subtypes, genetic counseling of patients, guidance to optimal treatment options, and screening of carrier relatives. (Clin Diabetol 2023; 12; 4: 232–238)
{"title":"Investigation of the Mutation Spectrum in Pediatric Patients with Maturity-Onset Diabetes of Youth (MODY): Experience from a Diagnostic Center in Türkiye","authors":"Neslihan Duzkale, C. Emiroğlu","doi":"10.5603/dk.a2023.0030","DOIUrl":"https://doi.org/10.5603/dk.a2023.0030","url":null,"abstract":"Objective: This study was aimed to determine the ge-netic background of pediatric patients with a clinical diagnosis of maturity-onset diabetes of youth (MODY). Materials and methods: In this study, MODY-related genes of 80 pediatric patients diagnosed with MODY in Türkiye between January 2016 and January 2022 were investigated using three different large gene panels and next-generation sequencing. Results: Causal variants were detected in the genes investigated in 16 (20%) of 80 patients included in the study. The GCK gene was responsible for the clinical findings in 13 (82%) of 16 patients with a molecular diagnosis, and the HNF1A , HNF1B , and ABCC8 genes in the remaining three patients. This study identified six of the detected genomic variants for the first time in the literature. Conclusions: MODY is a group of diseases that differ from each other in terms of clinical findings, treatment, progression, genetic etiopathogenesis and incidence. For this reason, genetic analyses using multigene panels will enable accurate identification of MODY subtypes, genetic counseling of patients, guidance to optimal treatment options, and screening of carrier relatives. (Clin Diabetol 2023; 12; 4: 232–238)","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85657232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Abdel-Aty, E. Moursi, E. Elsayed, Marwa Ahmed Salah, Sary Ibrahim Abdelsalam
Objective: This study was conducted to reveal the association of ANGPTL8 gene variant (Rs2278426 (C/T)) with metabolic syndrome in a cohort of Egyptian patients. Materials and methods: This study is a case control study that included 150 patients with metabolic syndrome and 150 healthy control subjects. All subjects were submitted to history taking and thorough physical examination and laboratory analysis. Genomic DNA was extracted and ANGPTL8 gene SNP (rs2278426) was detected by 5’ nuclease assay. The tested genotypes included homozygous genotypes for C allele (CC), homozygous genotypes for T allele (TT) and heterozygous genotypes (CT). Results: A total of 300 subjects were included in the study; group 1 included 150 patients with metabolic syndrome. 21.3% were males and 78.7% were females, and group 2 had 150 healthy subjects. 17.3% were males, and 82.7% were females. In the current study, the metabolic syndrome group showed dysregulation of lipids and fasting plasma glucose (FPG) with a statistically significant increase in body anthropometric measures. There was no statistically significant differ - ence in the distribution of the heterozygous genotype (C/T) relative to the wild-type genotype (C/C) in each of the two tested groups (p = 0.287 and 0.245 in the metabolic syndrome and control groups, respectively). Conclusions: There was no statistically significant dif - ference in the genotype distribution of ANGPTL8 gene variant (Rs2278426) genotypes between the metabolic syndrome and control groups. The homozygous recessive genotype for T allele (TT) was not detected in both tested groups. (Clin Diabetol 2023; 12; 4: 215–222)
{"title":"Association of Angiopoietin-Like Protein-8 Gene Variant (Rs2278426 (C/T)) in a Cohort of Egyptian Patients with Metabolic Syndrome: A Case-Control Study","authors":"T. Abdel-Aty, E. Moursi, E. Elsayed, Marwa Ahmed Salah, Sary Ibrahim Abdelsalam","doi":"10.5603/dk.a2023.0023","DOIUrl":"https://doi.org/10.5603/dk.a2023.0023","url":null,"abstract":"Objective: This study was conducted to reveal the association of ANGPTL8 gene variant (Rs2278426 (C/T)) with metabolic syndrome in a cohort of Egyptian patients. Materials and methods: This study is a case control study that included 150 patients with metabolic syndrome and 150 healthy control subjects. All subjects were submitted to history taking and thorough physical examination and laboratory analysis. Genomic DNA was extracted and ANGPTL8 gene SNP (rs2278426) was detected by 5’ nuclease assay. The tested genotypes included homozygous genotypes for C allele (CC), homozygous genotypes for T allele (TT) and heterozygous genotypes (CT). Results: A total of 300 subjects were included in the study; group 1 included 150 patients with metabolic syndrome. 21.3% were males and 78.7% were females, and group 2 had 150 healthy subjects. 17.3% were males, and 82.7% were females. In the current study, the metabolic syndrome group showed dysregulation of lipids and fasting plasma glucose (FPG) with a statistically significant increase in body anthropometric measures. There was no statistically significant differ - ence in the distribution of the heterozygous genotype (C/T) relative to the wild-type genotype (C/C) in each of the two tested groups (p = 0.287 and 0.245 in the metabolic syndrome and control groups, respectively). Conclusions: There was no statistically significant dif - ference in the genotype distribution of ANGPTL8 gene variant (Rs2278426) genotypes between the metabolic syndrome and control groups. The homozygous recessive genotype for T allele (TT) was not detected in both tested groups. (Clin Diabetol 2023; 12; 4: 215–222)","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82349584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Sharma, Amit Dey, J. George, Lakshmi Nagendra, S. Mittal, Ajoy Tewari, Ashish Birla, Ashish Prasad, Aushili M
{"title":"Low-Dose Glimepiride and Metformin Fixed-Dose Combination in treating Maturity-Onset Diabetes of the Young Type (MODY): A Cross Sectional Survey","authors":"B. Sharma, Amit Dey, J. George, Lakshmi Nagendra, S. Mittal, Ajoy Tewari, Ashish Birla, Ashish Prasad, Aushili M","doi":"10.5603/dk.a2023.0028","DOIUrl":"https://doi.org/10.5603/dk.a2023.0028","url":null,"abstract":"","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73576771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：